Applications of P2X3 acceptor conditioning agent benzimidazole compound in preparation of medicines used for treating respiratory diseases

Abstract

The invention discloses applications of a P2X3 acceptor conditioning agent benzimidazole compound in preparation of medicines used for treating respiratory diseases. The general formula of the P2X3 acceptor conditioning agent benzimidazole compound is disclosed in the invention. The P2X3 acceptor conditioning agent benzimidazole compound can be used for preparation of medicines used for treating and / or preventing and / or delaying and / or adjuvant therapy of respiratory diseases, is capable of improving COPD damaged pulmonary function obviously, reducing pulmonary artery high pressure obviously,improving lung tissue fibrosis deposition, possesses excellent treatment effect, is high in clinical application value, and is promising in prospect.

Description

technical field [0001] The invention relates to the application of P2X3 receptor modulator benzimidazole compound in the preparation of anti-respiratory disease medicine. Background technique [0002] Respiratory system disease is a kind of common disease, frequently-occurring disease, and main lesion is in trachea, bronchi, lung and chest cavity. What should be paid more attention to is that due to air pollution and other factors, chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD), chronic cough (chronic cough), lung cancer (lung cancer), pulmonary fibrosis (lung fibrosis), The morbidity and mortality of pulmonary arterial hypertension (pulmonary artery hypertension) and asthma (asthma) are increasing. [0003] Chronic obstructive pulmonary disease is a chronic inflammatory disease of the airways with not fully reversible airflow limitation. Long-term inhalation of harmful particles (such as cigarette smoke, dust, etc.) is closely related ...

AI Technical Summary

Problems solved by technology

[0010] Currently, diaminopyridine P2X3 and P2X2 / 3 receptor modulators have been reported in the literature for the treatment of acute, subacute or chronic cough (CN105682659A and WO2015027212A1), and there are also reports for the treatment of hypertension and migraine (WO2016004358A1), However, there are no reports on the use of P2X3 receptor modulators in the treatment of respiratory diseases such as COPD or PAH.

Images